• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Re-analysis of evidence suggests that PSA screening significantly reduces the risk for death from prostate cancer

byCaitlyn HuiandDeepti Shroff Karhade
September 4, 2017
in Chronic Disease, Endocrinology, Imaging and Intervention, Oncology, Public Health, Surgery, Urology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. PSA screening was associated with a reduction in risk for death from prostate cancer.

2. No differences in the effects of PSA screening were found between the European Randomized Study of Screening for Prostate Cancer (ERSPC) and the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO).

Evidence Rating Level: 2 (Good)

Study Rundown: Controversy exists regarding the utility of prostate-specific antigen (PSA) screening. In 2012, the U.S. Preventive Services Task Force stated that screening has a very low impact in terms of preventing death from prostate cancer. The Task Force utilized two studies, ERSPC and PLCO, to draw its conclusions. However, differences exist between these studies; the ERSPC concluded that screening had a 21% reduction in prostate cancer mortality, while the PLCO study found no difference in mortality between the control and intervention groups. As these studies differed significantly in terms of their design and practice settings, the authors of this paper aimed to formally test whether the effects of screening on prostate cancer mortality compared to no screening intervention different between the ERSPC and PLCO using Cox regression models. This study has several limitations. Mainly, the authors did not explicitly account for differences between trials with regards to cancer case characteristics and primary treatments. Overall, they found that with re-analysis of the evidence, PSA screening significantly reduces the risk of death from prostate cancer.

Click to read the study, published today in the Annals of Internal Medicine

Relevant Reading: The Impact of PSA Screening on Prostate Cancer Mortality and Overdiagnosis of Prostate Cancer in the United States

RELATED REPORTS

The Scan by 2 Minute Medicine®: Celebrity diagnoses spur screenings, athlete mental-health push, reality-TV heart lesson, and a sitcom PSA wave

Exercise improves sexual function in men with prostate cancer  

Genome classifiers may aid prostate cancer risk stratification and treatment

In-Depth [retrospective cohort]: The authors of this study compared two randomized controlled trials using Cox regression models, which adjusted for age and trial. Two analyses were performed: a traditional statistical analysis and an extended analysis that incorporated the mean lead time (MLT), which reflects the average time by which diagnosis is advanced by screening compared to the date of diagnosis without screening. Generally, the authors found that PSA screening reduced the risk of prostate cancer mortality. For example, they estimated that screening reduced risk for prostate cancer death by 7% to 9% per year of MLT. The ERSPC intervention group therefore had an approximate risk reduction of 27% to 32% and the PLCO had an approximate risk reduction of 25% to 31% compared to the control groups. Furthermore, it was observed that benefit of PSA screening increased with MLT (P = 0.0027 to 0.0032).

Image: CC/Wiki

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: prostate cancerprostate specific antigen
Previous Post

Sleep disordered breathing linked to impaired cognitive function

Next Post

Cardiovascular benefits of intensive systolic blood pressure control may outweigh risks of chronic kidney disease events

RelatedReports

The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Celebrity diagnoses spur screenings, athlete mental-health push, reality-TV heart lesson, and a sitcom PSA wave

July 2, 2025
Patient-reported outcomes differ significantly based on treatment in prostate cancer: The ProtecT trial
Chronic Disease

Exercise improves sexual function in men with prostate cancer  

May 24, 2025
BRAF V600E mutations linked with increased mortality in thyroid cancer
Oncology

Genome classifiers may aid prostate cancer risk stratification and treatment

January 20, 2025
Androgen deprivation in prostate cancer: intermittent may compromise survival
Chronic Disease

Radiotherapy and abiraterone improve survival in low-volume metastatic castration-sensitive prostate cancer

December 18, 2024
Next Post
American Academy of Pediatrics recommends standards for adverse event disclosures

Cardiovascular benefits of intensive systolic blood pressure control may outweigh risks of chronic kidney disease events

Implementation of pneumococcal vaccine programs linked to decreased antibiotic prescription

Antibiotic prescribing rates in pediatric emergency departments vary by race and ethnicity

Development of a risk index for colorectal cancer screening

Physician notification increases patient participation in colorectal cancer screening

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Time-restricted eating does not confer changes in sleep, mood, or quality of life
  • Commonly cited medication triggers may not increase risk of microscopic colitis among older adults
  • Ablation may reduce stroke risk, death, heart failure hospitalization in patients with atrial fibrillation
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.